Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VX-864 in Alpha-1 Antitrypsin Deficiency (PiZZ Genotype)
NCT05643495Phase 2Terminated
- Sponsor
- Vertex Pharmaceuticals
- Start
- Feb 2023
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of VX-864 in alpha-1 antitrypsin deficiency (AATD), sponsored by Vertex Pharmaceuticals. Started Feb 2023; status: terminated.
02
Drugs
VX-864
03
Conditions
alpha-1 antitrypsin deficiency (AATD)
Beyond the preview
Go deeper on NCT05643495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05643495.